Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland Sells 1,446 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland sold 1,446 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Kate Haviland also recently made the following trade(s):

• On Friday, November 29th, Kate Haviland sold 2,353 shares of Blueprint Medicines stock. The shares were sold at an average price of $96.60, for a total value of $227,299.80.

Blueprint Medicines Price Performance

NASDAQ BPMC opened at $115.63 on Friday. The stock has a market cap of $7.35 billion, a price-to-earnings ratio of -54.80 and a beta of 0.61. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The company’s 50 day moving average is $95.28 and its two-hundred day moving average is $95.48. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. Blueprint Medicines’s revenue for the quarter was up 126.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.20) EPS. As a group, research analysts anticipate that Blueprint Medicines Co. will post -3.67 earnings per share for the current year.

Hedge Funds Weigh In On Blueprint Medicines

Several large investors have recently made changes to their positions in BPMC. Amalgamated Bank raised its stake in Blueprint Medicines by 5.3% during the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 109 shares during the period. Vanguard Personalized Indexing Management LLC boosted its stake in Blueprint Medicines by 12.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,276 shares of the biotechnology company’s stock worth $461,000 after purchasing an additional 485 shares during the period. Hsbc Holdings PLC purchased a new stake in Blueprint Medicines during the 2nd quarter valued at approximately $1,060,000. Sei Investments Co. raised its position in shares of Blueprint Medicines by 15.4% during the second quarter. Sei Investments Co. now owns 52,986 shares of the biotechnology company’s stock valued at $5,711,000 after buying an additional 7,073 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in shares of Blueprint Medicines in the second quarter worth $7,458,000.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, November 15th. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Wells Fargo & Company cut their target price on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. JMP Securities reissued a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. began coverage on Blueprint Medicines in a report on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.72.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.